Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH. Miles Prince, M. D’Incan, Reinhard Dummer et al.|The Lancet|2017Cited by 580
Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancerXinyi Guo, Hu Nie, Wenwen Zhang et al.|Cancer Cell|2025Cited by 65